The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
Open accessAbstract
Purpose: Resistance to chemotherapy-induced apoptosis represents a major obstacle to cancer control. Overexpression of Bcl-2 is seen in multiple tumor types and targeting Bcl-2 may provide therapeutic benefit. A phase I study of navitoclax, a novel inhibitor of Bcl-2 family proteins, was conducted to evaluate safety, pharmacokinetics, and preliminary efficacy in patients with solid tumors. Patients and Methods: Patients enrolled to intermittent dosing cohorts received navitoclax on day −3, followed by dosing on days 1 to 14 of a 21-day cycle. Patients on continuous dosing received a 1-week lead-in dose of 150 mg followed by continuous daily administration. Blood samples were collected for pharmacokinetic analyses, biomarker analyses, and platelet monitoring. Results: Forty-seven patients, including 29 with small-cell lung cancer (SCLC) or pulmonary carcinoid, were enrolled between 2007 and 2008, 35 on intermittent and 12 on continuous dosing cohorts. Primary toxicities included diarrhea (40%), nausea (34%), vomiting (36%), and fatigue (34%); most were grade 1 or 2. Dose- and schedule-dependent thrombocytopenia was seen in all patients. One patient with SCLC had a confirmed partial response lasting longer than 2 years, and eight patients with SCLC or carcinoid had stable disease (one remained on study for 13 months). Pro-gastrin releasing peptide (pro-GRP) was identified as a surrogate marker of Bcl-2 amplification and changes correlated with changes in tumor volume. Conclusion: Navitoclax is safe and well tolerated, with dose-dependent thrombocytopenia as the major adverse effect. Preliminary efficacy data are encouraging in SCLC. Efficacy in SCLC and the utility of pro-GRP as a marker of treatment response will be further evaluated in phase II studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“clinical trial data suggest that the dose-limiting toxicities of obatoclax may preclude sufficient target inhibition, in contrast to ABT-263 (30, 34, 35).”
From mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 (2014) · cites this paper as [30]
Experimental — accuracy not yet measuredIn the citing paper
“The use of Bcl-xl inhibitors as senolytics is largely limited by their on-target and dose-limiting platelet toxicity.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [26]
In the citing paper
“Bcl-xl inhibition with ABT263 and other small molecular inhibitors induces platelet apoptosis and results in severe thrombocytopenia, which prevents the use of ABT263 and other Bcl-xl specific inhibitors in the clinic—even for cancer patients—because platelets solely depend on Bcl-xl for survival24–27.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [26]
In the citing paper
“Because both SCs and platelets, but not NCs, are primarily dependent on Bcl-xl for survival16–18,24–27 (Supplementary Fig. 1h), we evaluated the effects of PZ compared with ABT263 on the viability of WI38 NCs (Fig. 1g, left panel), IR-SCs (Fig. 1g, middle panel), and platelets (Fig. 1g, right panel).”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [26]
In the citing paper
“As reported, ABT263 was highly toxic to both WI38 IR-SCs (Fig. 1g, middle panel) and platelets16–18,24–27 (Fig. 1g, right panel; Supplementary Fig. 2).”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [26]
In the citing paper
“Therefore, PZ can selectively induce apoptosis in SCs, but not platelets, which are dependent on Bcl-xl for survival while having minimal toxicity to NCs that are less sensitive to Bcl-xl inhibition than SCs16–18,24–27.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Pardo, O. E., Arcaro, A., Salerno, G., Raguz, S., Downward, J., & Seckl, M. J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.a115.109006 · Cited by 153
RetractedPardo, O. E., Arcaro, A., Salerno, G., Raguz, S., Downward, J., & Seckl, M. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109006200 · Cited by 145
RetractedAn inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Certo, M. V., Moore, V. D. G., Nishino, M., Wei, G., Korsmeyer, S. J., Armstrong, S. A., & Letai, A. G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.027 · Cited by 1,278
van Delft, M. F., Wei, A. H., Mason, K. D., Vandenberg, C. J., Chen, L., Czabotar, P. E., Willis, S. N., Scott, C. L., Day, C. L., Cory, S., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.027 · Cited by 1,271
Programmed Anuclear Cell Death Delimits Platelet Life Span
Mason, K. D., Carpinelli, M. R., Fletcher, J. I., Collinge, J. E., Hilton, A. A., Ellis, S., Kelly, P. N., Ekert, P. G., Metcalf, D., Roberts, A. W., et al. (2007) · Cell · doi:10.1016/j.cell.2007.01.037 · Cited by 1,031 · cited 1×
“This is a mechanism-based toxicity induced by inhibition of Bcl-xL in circulating platelets,(13,18) which is required for platelet survival.(19,20) Here we describe a phase I dose-escalation study to evaluate the safety (with particular attention to platelet dynamics), pharmacokinetics, and preliminary efficacy of nav…”
BackgroundThe role of Bcl-2 family members in tumorigenesis
Kirkin, V., Joos, S., & Zörnig, M. (2003) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2003.08.009 · Cited by 567
Some practical improvements in the continual reassessment method for phase I studies
Goodman, S. N., ZAHURAK, M. L., & Piantadosi, S. (1995) · Statistics in Medicine · doi:10.1002/sim.4780141102 · Cited by 475
Bcl-2 family proteins are essential for platelet survival
Zhang, H., Nimmer, P. M., Tahir, S. K., Chen, J., Fryer, R. M., Hahn, K. R., Iciek, L. A., Morgan, S. J., Nasarre, M. C., Nelson, R., et al. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402081 · Cited by 427
Flagged first, then by citations
1 of the 39 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Ben-Ezra JM, 1994, Am J Pathol, 145, 1036
- Brambilla E, 1996, Am J Pathol, 149, 1941
Cited by
Sorted by citations
Items 401–500 of 616
Fernandez, E. G., Mai, W. X., Song, K., Bayley, N. A., Kim, J., Zhu, H., Pioso, M. S., Young, P., Andrasz, C. L., Cadet, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54138-9 · Cited by 15
Bcl-2 Family of Proteins as Therapeutic Targets in Genitourinary Neoplasms
Hall, C. P., Troutman, S. M., Price, D. K., Figg, W. D., & Kang, M. H. (2012) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2012.09.002 · Cited by 15
The Influential Role of BCL2 Family Members in Synovial Sarcomagenesis
Barrott, J. J., Zhu, J.-F., Smith-Fry, K., Susko, A. M., Nollner, D., Burrell, L. D., Pozner, A., Capecchi, M. R., Yap, J. T., Cannon‐Albright, L., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0315 · Cited by 15
Navitoclax combined with Alpelisib effectively inhibits Merkel cell carcinoma cell growth in vitro
Chteinberg, E., Wetzels, S., Gerritsen, W., Temmerman, L., van den Oord, J., Biessen, E. A. L., Kurz, A. K., Winnepenninckx, V. J. L., Zenke, M., Speel, E. M., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920975621 · Cited by 15
Schnorenberg, M. R., Hawley, K. M., Thomas-Toth, A. T., Watkins, E. A., Tian, Y. P., Ting, J., Leak, L. B., Kucera, I. M., Raczy, M. M., Kung, A. L., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c04112 · Cited by 14
Radiobiological Modifiers in Clinical Radiation Oncology: Current Reality and Future Potential
Allison, R. R. (2014) · Future Oncology · doi:10.2217/fon.14.174 · Cited by 14
Developmental Therapeutics in Myeloproliferative Neoplasms
Bose, P., & Verstovšek, S. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.02.014 · Cited by 15
Ryu, Y., Hall, C. P., Reynolds, C. P., & Kang, M. H. (2014) · Experimental Biology and Medicine · doi:10.1177/1535370214538745 · Cited by 14
Cellular senescence in cancer: Friend or fraud?
Chen, Q., Liu, J., Wu, J., Xiang, X., Zhou, X., Mi, J., Wei, J., Zou, X., & Wu, A. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101363 · Cited by 15
Exploiting the Synergy between Carboplatin and ABT-737 in the Treatment of Ovarian Carcinomas
Jain, H. V., Richardson, A., Meyer‐Hermann, M., & Byrne, H. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0081582 · Cited by 13
Lam, L. T., Zhang, H., Xue, J., Leverson, J. D., & Bhathena, A. (2015) · Cancer Cell International · doi:10.1186/s12935-014-0151-3 · Cited by 13
Accurate treatment of small cell lung cancer: Current progress, new challenges and expectations
Zhang, C., & Wang, H. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188798 · Cited by 13
Gong, Q., Wang, H., Zhou, M., Zhou, L., Wang, R., & Li, Y. (2023) · Medicinal Research Reviews · doi:10.1002/med.21999 · Cited by 13
Biomarkers of Therapeutic Response to BCL2 Antagonists in Cancer
Lam, L. T., Zhang, H., & Chyla, B. (2012) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-012-0003-6 · Cited by 13
Zacarías-Lara, O., Correa‐Basurto, J., & Bello, M. (2016) · Biopolymers · doi:10.1002/bip.22839 · Cited by 13
Sagara, A., Igarashi, K., Otsuka, M., Karasawa, T., Gotoh, N., Narita, M., Kuzumaki, N., Narita, M., & Katō, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164250 · Cited by 13
Opydo‐Chanek, M., Rak, A., Cierniak, A., & Mazur, L. (2017) · Toxicology in Vitro · doi:10.1016/j.tiv.2017.03.013 · Cited by 13
Inoue‐Yamauchi, A., & Oda, H. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.03.139 · Cited by 13
Priming Cancer Cells for Death
Reed, J. C. (2011) · Science · doi:10.1126/science.1215568 · Cited by 13
Energetic Fingerprinting of Ligand Binding to Paralogous Proteins: The Case of the Apoptotic Pathway
Ivanov, S. M., Huber, R. G., Alibay, I., Warwicker, J., & Bond, P. J. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00765 · Cited by 12
Yao, L., Li, Y., Wang, Q. K., Chen, T. X., Li, J., Wang, Y., Zhang, L., Li, S., Li, L., Lou, Q., et al. (2023) · Journal of Cancer · doi:10.7150/jca.85846 · Cited by 12
Bacca, L. F. G., Brandariz, J., Zacchi, F., Zivi, A., Mateo, J., & Labbé, D. P. (2025) · Gene · doi:10.1016/j.gene.2025.149774 · Cited by 12
Pesch, A. M., Chandler, B. C., Michmerhuizen, A. R., Carter, H. M., Hirsh, N. H., Wilder-Romans, K., Liu, M., Ward, T., Ritter, C. L., Nino, C. A., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0024 · Cited by 12
Targeting Oncogenic Mutant p53 and BCL-2 for Small Cell Lung Cancer Treatment
Neely, V. L., Manchikalapudi, A., Nguyen, K., Dalton, K. M., Hu, B., Koblinski, J. E., Faber, A. C., Deb, S., & Harada, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713082 · Cited by 12
Yang, J., Pradhan, R. S., Rosen, L. S., Graham, A. M., Holen, K. D., & Xiong, H. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12193 · Cited by 12
Self-citationPro-apoptotic meiogynin A derivatives that target Bcl-xL and Mcl-1
Desrat, S., Pujals, A., Colas, C., Dardenne, J., Gény, C., Favre, L., Dumontet, V., Iorga, B. I., Litaudon, M., Raphaël, M., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.09.004 · Cited by 12
Tada, M., Sumi, T., Tanaka, Y., Hirai, S., Yamaguchi, M., Miyajima, M., Niki, T., Takahashi, H., Watanabe, A., & Sakuma, Y. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.014 · Cited by 12
BCL-2 and BCL-xL in Cancer: Regulation, Function, and Therapeutic Targeting
Silva, J. P. N., Pinto, B. F., Silva, P. M. A., & Bousbaa, H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27021123 · Cited by 16
Manipulating the apoptotic pathway: potential therapeutics for cancer patients
Bates, D. J. P., & Lewis, L. D. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12193 · Cited by 11
Makinwa, Y., Luo, Y., Musich, P. R., & Zou, Y. (2024) · Cancers · doi:10.3390/cancers16122199 · Cited by 12
Dual targeting of HSP90 and BCL-2 in breast cancer cells using inhibitors BIIB021 and ABT-263
Tosun, N. G., & Kaplan, Ö. (2025) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07587-1 · Cited by 11
Bcl-xL activity influences outcome of the mitotic arrest
Suleimenov, M., Bekbayev, S., Ten, M., Suleimenova, N., Tlegenova, M., Nurmagambetova, A., Kauanova, S., & Vorobjev, I. A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.933112 · Cited by 11
Lu, B., Liu, Y., Yao, Y., Zhu, D., Zhang, X., Dong, K., Xu, X., Lv, D., Zhao, Z., Zhang, H., et al. (2024) · Biology Direct · doi:10.1186/s13062-024-00516-8 · Cited by 11
Targeting Apoptotic Pathways in Acute Myeloid Leukaemia
Sillar, J. R., & Enjeti, A. K. (2019) · Cancers · doi:10.3390/cancers11111660 · Cited by 11
Qin, X., Presser, A. G., Johnson, L., Matoba, Y., Shay, B., Xu, W., Choiniere, J., Fraser, C., Garbicz, F., Spetz, J. K. E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.24.661170 · Cited by 11
Advancement Opportunities and Endeavor of Innovative Targeted Therapies for Small Cell Lung Cancer
Ouyang, W., Xu, Z., Guan, S., Hu, Y., Gou, X., Liu, Z., Guo, W., Huang, Y., Zhang, L., Zhang, X., et al. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.105973 · Cited by 10
Exploiting the Biginelli reaction: nitrogen-rich pyrimidine-based tercyclic α-helix mimetics
Lim, Z., Duggan, P. J., Wan, S. S., Lessène, G., Meyer, A. G., & Tuck, K. L. (2015) · Tetrahedron · doi:10.1016/j.tet.2015.12.044 · Cited by 10
Cristofano, F. R. D., Fong, M., Huntington, K. E., Carneiro, B. A., Zhou, L., & El‐Deiry, W. S. (2023) · PubMed Central · Cited by 10
Cellular Senescence and Senolytic Agents: Recent Updates on Their Role and Applications
Chandrakar, L., Ambatwar, R., & Khatik, G. L. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266273698231107110956 · Cited by 10
Chen, P., Wang, Y., & Zhou, B. (2024) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2024.111918 · Cited by 10
Lewis, C. J., & de Grey, A. D. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2330425 · Cited by 10
König, C., Hillert-Richter, L. K., Ivanisenko, N. V., Иванисенко, В. А., & Lavrik, I. N. (2020) · Scientific Reports · doi:10.1038/s41598-020-76079-1 · Cited by 10
Pyrogallol Induces Apoptosis in Human Platelets
Bruges, G., Venturini, W., Crespo, G., & López-Zambrano, M. (2018) · Folia Biologica · doi:10.14712/fb2018064010023 · Cited by 10
Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development
Wijesinghe, P., & Bollig-Fischer, A. B. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24932-2_1 · Cited by 9
Dual targeting Bcl-2 and Bcl-xL augments osteosarcoma response to doxorubicin
Cao, C., Pei, Y., Yu, H., & Qi, H. (2023) · Journal of Chemotherapy · doi:10.1080/1120009x.2023.2220583 · Cited by 9
Inhibition of Bcl-2 or IAP proteins does not provoke mutations in surviving cells
Shekhar, T. M., Green, M. M., Rayner, D. M., Miles, M. A., Cutts, S. M., & Hawkins, C. J. (2015) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2015.04.005 · Cited by 9
Liu, Z., Luo, X., Mo, Y., Zhao, P., Wang, H., Fang, Y., & Xu, Y. (2022) · Pharmaceuticals · doi:10.3390/ph15101244 · Cited by 9
Wang, X., Gu, Z., LI, G., Zhang, S., CAO, Z., Yang, Z., & Liu, G. (2014) · Oncology Reports · doi:10.3892/or.2014.3228 · Cited by 9
Machado, V., Serrano, J., & Galián, J. (2016) · Folia Biologica · doi:10.3409/fb64_1.23 · Cited by 9
Molecular Mechanisms of Senescence and Implications for the Treatment of Myeloid Malignancies
Ernst, P., & Heidel, F. H. (2021) · Cancers · doi:10.3390/cancers13040612 · Cited by 9
Kourti, M., & Kontoghiorghes, G. J. (2025) · Antioxidants · doi:10.3390/antiox15010015 · Cited by 11
A molecular approach to triple-negative breast cancer: targeting the Notch signaling pathway
Pardo, I., Fagundes, P. B., Oliveira, R. B. S., & Campregher, P. V. (2024) · Einstein (São Paulo) · doi:10.31744/einstein_journal/2024rw0552 · Cited by 8
Novel BH4-BCL-2 Domain Antagonists Induce BCL-2-Mediated Apoptosis in Triple-Negative Breast Cancer
Kanakaveti, V., Sakthivel, R., Kanumuri, R., Balasubramanian, V., Saravanan, R., Ezhil, I., Pitani, R., Venkatraman, G., Rayala, S. K., & Gromiha, M. M. (2022) · Cancers · doi:10.3390/cancers14215241 · Cited by 8
Approaches to augment CAR T-cell therapy by targeting the apoptotic machinery
Karlsson, H. (2016) · Biochemical Society Transactions · doi:10.1042/bst20150253 · Cited by 8
Carvalho, A. M., Greene, M. K., Smyth, P., Mutch, A., McLaughlin, K. M., Cairns, L. V., Mills, K., McCloskey, K. D., & Scott, C. J. (2024) · Biomacromolecules · doi:10.1021/acs.biomac.4c00672 · Cited by 7
Scott, S. C., Farago, A. F., Lai, W. V., ZAHURAK, M. L., Rudek, M. A., Murray, J., Carducci, M. A., Uziel, T., Takebe, N., Gore, S. D., et al. (2025) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-025-04760-1 · Cited by 7
Self-citationCellular senescence in the cancer microenvironment
Meguro, S., & Nakanishi, M. (2025) · The Journal of Biochemistry · doi:10.1093/jb/mvaf001 · Cited by 7
Phosphorylated Bcl-2 and Mcl-1 as prognostic markers in small cell lung cancer
Chowdry, R. P., Sica, G., Kim, S., Chen, Z., Goodman, A. M., Alexis, D., Deng, X., & Owonikoko, T. K. (2016) · Oncotarget · doi:10.18632/oncotarget.7485 · Cited by 7
Boulet, C., Siddiqui, G., Gaynor, T. L., Doerig, C., Creek, D. J., & Carvalho, T. G. (2022) · Microorganisms · doi:10.3390/microorganisms10040824 · Cited by 7
Clerc, P., Carey, G. B., Mehrabian, Z., Wei, M., Hwang, H., Girnun, G. D., Chen, H., Martin, S. S., & Polster, B. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042487 · Cited by 7
Greystoke, A., Harris, G., Jenkins, M. A., Goonetilleke, D., Moore, D., Lancashire, M., Ranson, M., Hughes, A. M., Clack, G., & Dive, C. (2013) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2013.06.010 · Cited by 7
Self-citationDu, X., Pu, X., Wang, X., Zhang, Y., Jiang, T., Ge, Y., & Zhu, H. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.938250 · Cited by 6
Zhang, Z., Liang, L., Li, L., Fan, Y., Liu, Y., He, Z., Wu, X., Cong, L., Jiang, Y., & Wan, T. (2025) · Cancer Gene Therapy · doi:10.1038/s41417-025-00946-0 · Cited by 6
New strategies for the treatment of ovarian cancer
Robinson, E., Fisher, N. C., Stamelos, V. A., Redman, C. W. E., & Richardson, A. (2014) · Biochemical Society Transactions · doi:10.1042/bst20130203 · Cited by 6
McNamara, M. C., Hosios, A. M., Torrence, M. E., Zhao, T., Fraser, C. S., Wilkinson, M. E., Kwiatkowski, D. J., Henske, E. P., Wu, C., Sarosiek, K. A., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105458 · Cited by 6
RBP2 Promotes Adult Acute Lymphoblastic Leukemia by Upregulating BCL2
Wang, X., Zhou, M., Fu, Y., Sun, T., Chen, J., Qin, X., Yu, Y., Jia, J., & Chen, C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152142 · Cited by 6
Sahoo, S., Suvarna, S., Chandra, A., Wahi, S., Kumar, P., & Khanna, G. (2013) · PubMed · Cited by 6
Siddik, Z. H. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-396521-9.00012-7 · Cited by 6
Badr, G., Zahran, A. M., Omar, H. E.-D. M., Barsoum, M. A., & Mahmoud, M. H. (2019) · Nutrition and Cancer · doi:10.1080/01635581.2019.1595054 · Cited by 6
He, Y., Zheng, G., & Zhou, D. (2020) · Healthy ageing and longevity · doi:10.1007/978-3-030-44903-2_1 · Cited by 6
Jensen, R. T., & Moody, T. W. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-385095-9.00069-5 · Cited by 6
Almansoori, A., Bhamidimarri, P. M., Bendardaf, R., & Hamoudi, R. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s345336 · Cited by 6
Luffman, N., Ahmadinejad, F., Finnegan, R., Raymond, M., Gewirtz, D. A., & Harada, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136185 · Cited by 5
Qiu, F., Tao, Y., Chen, Y., Shen, Z., Huang, X., Tan, W., Huang, T., & Cao, X. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116731 · Cited by 6
Barve, A., Dabas, P., Cornwell, A., Sriram, P., Kopyov, O. V., Zhai, M., Kooienga, E., Kelley, Z., Johnson, J., Myers, J., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adv0628 · Cited by 6
Suzuki, M., Kobayashi, H., Hara, D., & Hanaoka, H. (2024) · Cancer Medicine · doi:10.1002/cam4.7381 · Cited by 5
Bcl-2 Family and Their Therapeutic Potential
Liu, Q., Chi, X., Leber, B. F., & Andrews, D. W. (2013) · Springer eBooks · doi:10.1007/978-1-4614-9302-0_4 · Cited by 5
Yang, Q., Lu, Y., & Du, A. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18046 · Cited by 5
Tang, X., Hu, J., Fan, X., Su, H., Li, M., Zhang, L., & Ma, D. (2025) · Immunity & Ageing · doi:10.1186/s12979-025-00541-9 · Cited by 4
PROTAC-mediated degradation of Bcl-xL potentiates target therapy in preclinical melanoma models
Valentini, E., Gentile, G., Martile, M. D., D’Aguanno, S., Brignone, M., Stefano, A. M. D., Caprio, M. D., Melucci, E., Botti, C., Pelle, F., et al. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03635-w · Cited by 4
Gifford, G. K., Stevenson, W. S., & Best, G. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1795156 · Cited by 4
Scott, S. C., Anders, N. M., He, P., Hemingway, A., Gore, S. D., Hann, C. L., & Rudek, M. A. (2021) · Biomedical Chromatography · doi:10.1002/bmc.5289 · Cited by 4
Self-citationMiscellaneous small- molecule and biological approaches to targeted cancer therapy
Avendaño, C., & Menéndez, J. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818549-0.00016-9 · Cited by 4
Protein–Protein Interaction Inhibitors in Cancer
Hardcastle, I. R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12392-3 · Cited by 5
Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia
Fatima, N., Crassini, K. R., Thurgood, L. A., Shen, Y., Christopherson, R. I., Kuss, B. J., Mulligan, S. P., & Best, G. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2019.111 · Cited by 4
Small Molecules As pro-apoptotic Anticancer Agents
Seneci, P. (2012) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.12.41 · Cited by 4
Protein–Protein Interaction Inhibitors
Hardcastle, I. R. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2017_27 · Cited by 4
Discovery of Inhibitors of Protein–Protein Interactions Using Fragment‐Based Methods
Wang, F., & Fesik, S. W. (2016) · Methods and principles in medicinal chemistry · doi:10.1002/9783527683604.ch16 · Cited by 4
Elimination of docetaxel-induced senescence attenuates malignant progression in RB1-deficient CRPC
Su, H., Huang, L., Xia, W., Tang, D. G., Zhou, J., & Yang, G. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01126-w · Cited by 3
Park, W. H. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178382 · Cited by 3
The Yin and Yang of cellular senescence in ischemia-induced myocardial injury
Gudenberg, R. W. V., Iske, J., Roeschl, T., Stawowy, P., Kirkland, J. L., Ruhparwar, A., & Tullius, S. G. (2025) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2025.12.004 · Cited by 3
Vardon, A., Haston, S., Hamdi, H., Cooksley, G., Guiho, R., Carvalho, D. M., Carter, R., Boult, J. K. R., Gharai, D., Cloete, I., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-32676-6 · Cited by 3
Cellular senescence in lung cancer immune microenvironment and senotherapeutic opportunities
Xu, Z., Liu, F., Huang, S., & Chu, Q. (2026) · iScience · doi:10.1016/j.isci.2026.114673 · Cited by 4
Natural killer cell-based senotherapy: a promising strategy for healthy aging
中澤務, Yamanishi, R., Morimoto, T., & Matusda, R. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1737572 · Cited by 3
Bcl-Xl is Translocated to the Nucleus Via Ctbp2 to Epigenetically Promote Metastasis
Zhang, T., Li, S., Tan, Y. A., Chen, X. '., Zhang, C., Chen, Z., Mishra, B., Na, J., Choi, S., Shin, S. J., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2024.217240 · Cited by 3
Valproic Acid Enhances Venetoclax Efficacy in Targeting Acute Myeloid Leukemia
Kawakatsu, R., Tadagaki, K., Yamasaki, K., Kuwahara, Y., & Yoshida, T. (2025) · Diseases · doi:10.3390/diseases13010010 · Cited by 3
Selecting efficacious Bcl-2 family inhibitors for optimal clinical outcome.
Muqbil, I., & Mohammad, R. M. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.09.15 · Cited by 3
A computational perspective for tailor-made selective Mcl-1 and Bcl-XL inhibitors
Huang, D., Wang, Y., Hu, B., Luo, Z., Huang, J., Wang, J., & Zhang, F. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.132269 · Cited by 3
Network-Based Molecular Features Selection to Predict the Drug Synergy in Cancer Cells
Aini, S., Kusuma, W. A., Hardhienata, M. K. D., & Mushthofa (2023) · Journal of Electronics Electromedical Engineering and Medical Informatics · doi:10.35882/jeemi.v5i3.307 · Cited by 3
Zhuang, K., Zhang, L., Zhang, X., Tang, H., Zhang, J., Yan, Y., Han, K., & Guo, H. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.3983 · Cited by 3
Metadata
- Authors
- Gandhi, L., Camidge, D. R., Ribeiro de Oliveira, M., Bonomi, P., Gandara, D., Khaira, D., Hann, C. L., McKeegan, E. M., Litvinovich, E., Hemken, P. M., Dive, C., Enschede, S. H., Nolan, C., Chiu, Y.-L., Busman, T., Xiong, H., Krivoshik, A. P., Humerickhouse, R., Shapiro, G. I., & Rudin, C. M.
- Affiliations
- Rush University Medical Center (US)
- From the Dana-Farber Cancer Institute, Boston, MA; University of Colorado Cancer Center, Aurora, CO; Northwest Medical Specialties, Tacoma, WA; Rush University Medical Center, Chicago; Abbott Laboratories, Abbott Park, IL; University of California Davis Cancer Center, Sacramento, CA; Sunterra Oncology Associates, Phoenix, AZ; Johns Hopkins University, Baltimore, MD; and Paterson Institute for Cancer Research, University of Manchester, United Kingdom.
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2011-03-01
- Volume
- 29
- Issue
- 7
- Pages
- 909-916
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC4668282
- OpenAlex
- W2119316461
- Cited by
- 603
- References
- 39
- Citations by year
- 2026: 35 · 2025: 28 · 2024: 30 · 2023: 34 · 2022: 32 · 2021: 37 · 2020: 39 · 2019: 29 · 2018: 33 · 2017: 31 · 2016: 40 · 2015: 46 · 2014: 57 · 2013: 54 · 2012: 51
- FWCI
- 24.82
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Funders
- National Cancer Institute (P30CA006973)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- navitoclax, BCL-2 inhibitor, small cell lung cancer, bronchial carcinoid, thrombocytopenia, progastrin-releasing peptide, apoptosis resistance, pharmacokinetics, safety and tolerability, intermittent dosing, continuous dosing, surrogate markers
- MeSH terms
- Administration, Oral, Aged, Aged, 80 and over, Aniline Compounds, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Neoplasms, Prognosis, Sulfonamides, Survival Analysis, Treatment Outcome, Risk Assessment, Genes, bcl-2, Maximum Tolerated Dose, Small Cell Lung Carcinoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
